-+ 0.00%
-+ 0.00%
-+ 0.00%

Bausch Health Canada Announces Expanded Public Reimbursement For PrOKEDI 75 Mg And 100 Mg, With Coverage Now Available In Seven Provinces And Multiple Federal Drug Plans

Benzinga·10/19/2026 12:10:06

PrOKEDI® is now listed in Ontario, Quebec, British Columbia, Alberta, Saskatchewan, Nova Scotia and Prince Edward Island, as well as through federal drug plans administered by the Non-Insured Health Benefits Program (NIHB), Veterans Affairs Canada (VAC), the Department of National Defence (DND) and Correctional Service Canada (CSC). 

PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults.1 PrOKEDI® is designed to provide rapid attainment of clinically relevant risperidone plasma concentrations, followed by sustained release over the four-week dosing interval, without the need for oral supplementation or a loading dose.